ARTICLE | Clinical News
C225: Began Phase III trial
March 15, 1999 8:00 AM UTC
ImClone Systems Inc. (IMCL), New York, N.Y. Product: C225 Business: Cancer Therapeutic category: Antibody Target: Epidermal growth factor (EGF) receptor Description: Monoclonal antibody against the ...